Nobel winner Tanaka to develop new mass spectroscopy device

Nobel winner Tanaka to develop new mass spectroscopy device

KYOTO, Japan - Koichi Tanaka, co-winner of the 2002 Nobel Prize in Chemistry, shows off his card at a news conference in Kyoto on March 28. Tanaka, who formally launched his research institute, said he hopes to develop a new mass spectroscopy device that can contribute to swift analysis of illnesses and development of new drugs.

  • Product Code
  • ILEA001096197
  • Registered date
  • 2003/3/28 00:00:00
  • Credit
  • Kyodo / Kyodo News Images
  • Media source
  • 2003 Kyodo News
  • Media size
  • 1864 × 1713 pixel
  • Resolution
  • dpi
  • Deployment size
  • 950.33(KB)*
  • Special instruction

*File size when opened in Photoshop, etc.

Similar Images & Videos
    Fast Retailing chief to donate 10 bil. yen to medical research

    Fast Retailing chief to donate 10 bil. yen to medical research

    Tadashi Yanai (C), chairman and CEO of Fast Retailing Co., the operator of casual wear chain Uniqlo, poses for a photo with two Nobel Prize winners -- Tasuku Honjo (L) and Shinya Yamanaka -- at a press conference in Kyoto on June 24, 2020, after announcing that he will donate a total of 10 billion yen ($93 million) to Kyoto University to support its medical research under the two scientists. (Kyodo) ==Kyodo
      Fast Retailing chief to donate 10 bil. yen to medical research

      Fast Retailing chief to donate 10 bil. yen to medical research

      Tadashi Yanai, chairman and CEO of Fast Retailing Co., the operator of casual wear chain Uniqlo, speaks at a press conference in Kyoto on June 24, 2020, announcing that he will donate a total of 10 billion yen ($93 million) to Kyoto University to support its medical research under two Nobel Prize winners -- Tasuku Honjo and Shinya Yamanaka. (Kyodo) ==Kyodo
        Press conference on the identification of existing drugs in Japan

        Press conference on the identification of existing drugs in Japan

        The photo shows Professor Junichiro Inoue of the Institute of Medical Science, University of Tokyo taking off his mask for explanation. (March 18, 2020, Yasuda Auditorium, University of Tokyo, Bunkyo-ku, Tokyo; Credit: Nikkan Kogyo Shimbun / Kyodo News Images)
          Press conference on the identification of existing drugs in Japan

          Press conference on the identification of existing drugs in Japan

          Photo shows Yuji Yamanashi, Director of the Institute of Medical Science, University of Tokyo, at a press conference. (March 18, 2020, Yasuda Auditorium, The University of Tokyo, Bunkyo-ku, Tokyo; Credit: Nikkan Kogyo Shimbun / Kyodo News Images)
            Press conference on the identification of existing drugs in Japan

            Press conference on the identification of existing drugs in Japan

            Photo shows Professor Junichiro Inoue of the Institute of Medical Science, University of Tokyo, at a press conference. (March 18, 2020, Yasuda Auditorium, The University of Tokyo, Bunkyo-ku, Tokyo; Credit: Nikkan Kogyo Shimbun / Kyodo News Images)
              Press conference on the identification of existing drugs in Japan

              Press conference on the identification of existing drugs in Japan

              Photo shows Professor Junichiro Inoue of the Institute of Medical Science, University of Tokyo, at a press conference. (March 18, 2020, Yasuda Auditorium, The University of Tokyo, Bunkyo-ku, Tokyo; Credit: Nikkan Kogyo Shimbun / Kyodo News Images)
                Press conference on the identification of existing drugs in Japan

                Press conference on the identification of existing drugs in Japan

                Photo shows Yuji Yamanashi, Director of the Institute of Medical Science, University of Tokyo, at a press conference. (March 18, 2020, Yasuda Auditorium, The University of Tokyo, Bunkyo-ku, Tokyo; Credit: Nikkan Kogyo Shimbun / Kyodo News Images)
                  Press conference on the identification of existing drugs in Japan

                  Press conference on the identification of existing drugs in Japan

                  Photo shows Makoto Gogami, President of the University of Tokyo, at a press conference. (March 18, 2020, Yasuda Auditorium, The University of Tokyo, Bunkyo-ku, Tokyo; Credit: Nikkan Kogyo Shimbun / Kyodo News Images)
                    Professor Inoue of University of Tokyo, announce the identification of a new coronavirus drug candidate

                    Professor Inoue of University of Tokyo, announce the identification of a new coronavirus drug candidate

                    Professor Junichiro Inoue and his colleagues at the University of Tokyo's Institute of Medical Science held a press conference on April 18 and announced that they had identified nafamostat. Nafamostat has been used for more than 30 years in Japan, and early clinical trials are expected to be conducted. The clinical research is expected to start by the beginning of April in cooperation with the National Center for Global Health and Medicine and others. When the new corona infects humans, proteins on the surface of the virus and proteins on the surface of human cells bind to each other, causing the outer membrane of the virus to fuse with the membrane of human cells. As a result, ribonucleic acid (RNA), which is the genetic information of the new corona, enters the human cell, and the virus multiplies. (March 18, 2020, Yasuda Auditorium, The University of Tokyo, Bunkyo-ku, Tokyo; Credit: Nikkan Kogyo Shimbun / Kyodo News Images)
                      Press conference on the identification of existing drugs in Japan

                      Press conference on the identification of existing drugs in Japan

                      Photo shows Kohei Miyazono, Executive Vice President (Research) of the University of Tokyo, at a press conference. (March 18, 2020, Yasuda Auditorium, The University of Tokyo, Bunkyo-ku, Tokyo; Credit: Nikkan Kogyo Shimbun / Kyodo News Images)